Premium
ARE THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDELINES THAT PROMULGATE ACTIVE SURVEILLANCE FOR LOW‐RISK PROSTATE CANCER JUSTIFIED BY THE AVAILABLE EVIDENCE?
Author(s) -
Parker Chris,
Graham John
Publication year - 2009
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2009.08395_3.x
Subject(s) - medicine , guideline , disease , prostate cancer , watchful waiting , prostatectomy , randomized controlled trial , intensive care medicine , excellence , clinical trial , evidence based medicine , intervention (counseling) , cancer , family medicine , alternative medicine , surgery , pathology , psychiatry , political science , law